Trialant
Platform
Home
Studies
Other
Contact Us
Terms of Service
Privacy Policy
Toggle Sidebar
Studies
Study
JSON
Overview
Key facts that identify this study and show where it stands today.
Description
What the study is about and why it is being run, in the researchers' own words.
Conditions
The medical conditions and diseases this study investigates.
Interventions
The treatments and procedures being evaluated in this study.
Participation
Who can join this study and the criteria used to decide.
Design
How the study is designed and how its participant groups are organized.
Contacts
The people to reach with questions about this study or how to join it.
Locations
Where the study is run and whether each site is currently recruiting.
Collaborators
The organizations and people involved in this study.
Similar Studies
Other registered studies that closely resemble this one.
Workspace
Home
Studies
Collections
Views
Contact Us
Terms of Service
Privacy Policy
Sign up
NCT03127618
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT03178071
No longer available
Expanded Access
Updated Nov 4, 2019
Lorlatinib Continuation Study
NCT05144997
Active, not recruiting
Interventional
Phase 4
Updated Dec 17, 2025
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
NCT03909971
Completed
Interventional
Phase 2
Updated Nov 5, 2025
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
NCT04541706
Completed
Interventional
Phase 4
Updated Dec 20, 2024
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
NCT06487078
Recruiting
Interventional
Not Applicable
Updated May 6, 2026
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
NCT03505554
Completed
Interventional
Phase 2
Updated Jun 10, 2026
Lorlatinib - PF-06463922 | NCT03127618 | Trialant
Save
Share
Approved for marketing
Expanded Access
Updated May 15, 2020
Lorlatinib - PF-06463922
ClinicalTrials.gov ID
NCT03127618
Lead Sponsor
Pfizer
INDUSTRY
Overall Status
Approved for marketing
Study Type
Expanded Access
Last Update Posted
May 15, 2020
Actual
Brief Summary
Lorlatinib expanded access program
No conditions
There are no conditions for this study.
Lorlatinib
Ages Eligible for Study
Adult (18-64)
Older Adult (65+)
Sexes Eligible for Study
No data available
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Adult, Senior
Exclusion Criteria:
-
No design
There is no design for this study.
No central contacts
There are no central contacts for this study.
No locations
There are no locations for this study.
Lead Sponsor
Pfizer
INDUSTRY